Study registration: *
Publication Haas E, Lancet, 2021
Dates: 2021-01-24 to 2021-04-03
Funding: Mixed (The Israel MoH and Pfizer separately provided in-kind support to this study. No funding was exchanged between the Israel MoH and Pfizer. )
Conflict of interest: Yes (FJA, JMM, FK, GM, KP, JS, DLS, and LJ hold stock and stock options in Pfizer. All other authors declare no competing interests.)

Methods

Study design:Cohort
Description of participants: Adults (16 years and older) with no history of COVID-19 in Israel
Inclusion criteria:
  • Israel resident
  • 16 years and older

Exclusion criteria:
  • Individuals with previous SARS-CoV-2 infection were excluded from person-day estimates

Follow-up duration (months): 2.3
Vaccines:
  • 2 doses of BNT162b2
Variant description :
Variant name: Alpha
Evidence: Indirect evidence (prevalence of variant in the population: 94ยท5% )
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Unclear
Data accessibility: The individual-level data used in this study are sensitive and cannot be publicly shared. Requests for data should be made to the Ministry of Health of Israel. Aggregated surveillance data are freely available online at https://data.gov.il/dataset/covid-19.
General comment Covid related mortality extracted for all cause mortality.Concerns over the lack of adjustment for important confounders, potential misclassificiation of the infection and symptomatic outcomes, and no pre-defined statistical plan available.